ArticleCurrent drug targets2012
Bacterial cell wall compounds as promising targets of antimicrobial agents I. Antimicrobial peptides and lipopolyamines.
Article in Current drug targets, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 84 citations in OpenAlex.
- Ethnobotanical importance and bioactivity of wild herbal teas from District Poonch Azad Jammu and Kashmir.Scientific reports · 2026Article
- Molecular Mechanisms of Bacterial Resistance to Antimicrobial Peptides in the Modern Era: An Updated Review.Microorganisms · 2024Review
- Evaluation of antioxidant and antibacterial properties of dehydrocostus lactone isolated fromHealth science reports · 2024Article
- The Effects of Grape Seed Oligomeric Proanthocyanidin and Nisin on Dental Pulp Stem Cells.Acta stomatologica Croatica · 2024Article
- The antimicrobial effect of different vitamin D compounds onJournal of oral microbiology · 2024Article
- Antibacterial effectiveness of different zinc salts onThe Saudi dental journal · 2023Article
- Antioxidant and antibacterial activities of the rhizome extract ofJournal of advanced veterinary and animal research · 2023Article
- Customized biofilm device for antibiofilm and antibacterial screening of newly developed nanostructured silver and zinc coatings.Journal of biological engineering · 2023Article
- Characterisation and Antibacterial Properties of Novel Biodegradable Films Based on Alginate and Roselle (Waste and biomass valorization · 2022Article
- Engineering a genome-reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo.Molecular systems biology · 2021Article
- Interest of Homodialkyl Neamine Derivatives against ResistantInternational journal of molecular sciences · 2021Article
- Antimicrobial Peptides with Antibacterial Activity against Vancomycin-ResistantInternational journal of molecular sciences · 2021Review
- The antibacterial effects of vitamin D3 against mutans streptococci: an in vitro study.European oral research · 2021Article
- Silver-doped bioactive glass particles for in vivo bone tissue regeneration and enhanced methicillin-resistant Staphylococcus aureus (MRSA) inhibition.Materials science & engineering. C, Materials for biological applications · 2021Article
- Exploring Phytochemicals for Combating Antibiotic Resistance in Microbial Pathogens.Frontiers in pharmacology · 2021Review
- Cationic π-Conjugated Polyelectrolyte Shows Antimicrobial Activity by Causing Lipid Loss and Lowering Elastic Modulus of Bacteria.ACS applied materials & interfaces · 2020Article
- Biomimetic Functional Surfaces towards Bactericidal Soft Contact Lenses.Micromachines · 2020Review
- Antimicrobial Property and Mode of Action of the Skin Peptides of the Sado Wrinkled Frog,Antibiotics (Basel, Switzerland) · 2020Article
- Phytosynthesized Metallic Nanoparticles-between Nanomedicine and Toxicology. A Brief Review of 2019's Findings.Materials (Basel, Switzerland) · 2020Review
- Insights Into Mechanisms of Antimicrobial Photodynamic Action Toward Biofilms Using Phenalen-1-One Derivatives as Photosensitizers.Frontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 5 countries.
Funding
Abstract
The first barrier that an antimicrobial agent must overcome when interacting with its target is the microbial cell wall. In the case of Gram-negative bacteria, additional to the cytoplasmic membrane and the peptidoglycan layer, an outer membrane (OM) is the outermost barrier. The OM has an asymmetric distribution of the lipids with phospholipids and lipopolysaccharide (LPS) located in the inner and outer leaflets, respectively. In contrast, Gram-positive bacteria lack OM and possess a much thicker peptidoglycan layer compared to their Gram-negative counterparts. An additional class of amphiphiles exists in Gram-positives, the lipoteichoic acids (LTA), which may represent important structural components. These long molecules cross-bridge the entire cell envelope with their lipid component inserting into the outer leaflet of the cytoplasmic membrane and the teichoic acid portion penetrating into the peptidoglycan layer. Furthermore, both classes of bacteria have other important amphiphiles, such as lipoproteins, whose importance has become evident only recently. It is not known yet whether any of these amphiphilic components are able to stimulate the immune system under physiological conditions as constituents of intact bacteria. However, all of them have a very high pro-inflammatory activity when released from the cell. Such a release may take place through the interaction with the immune system, or with antibiotics (particularly with those targeting cell wall components), or simply by the bacterial division. Therefore, a given antimicrobial agent must ideally have a double character, namely, it must overcome the bacterial cell wall barrier, without inducing the liberation of the pro-inflammatory amphiphiles. Here, new data are presented which describe the development and use of membrane-active antimicrobial agents, in particular antimicrobial peptides (AMPs) and lipopolyamines. In this way, essential progress was achieved, in particular with respect to the inhibition of deleterious consequences of bacterial infections such as severe sepsis and septic shock.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.